Bezafibrate lowers VLDL concentrations without modifying its structure.
Kazumi
T
T
Department of Medicine, Hyogo Medical Center for Adults, Akashi, Japan.
Yoshino
G
G
Matsuba
K
K
Iwai
M
M
Iwatani
I
I
Kasama
T
T
Yoshida
M
M
Baba
S
S
D000368:Aged; D053304:Apolipoprotein C-II; D001056:Apolipoproteins C / Q000097:blood; D001629:Bezafibrate / Q000494:pharmacology*; D002784:Cholesterol / Q000097:blood; D005260:Female; D006801:Humans; D006953:Hyperlipoproteinemia Type IV / Q000097:blood; D008055:Lipids / Q000097:blood; D008079:Lipoproteins, VLDL / Q000097:blood*; D008297:Male; D008875:Middle Aged; D015394:Molecular Structure; D014280:Triglycerides / Q000097:blood
D053304:Apolipoprotein C-II; D001056:Apolipoproteins C; D008055:Lipids; D008079:Lipoproteins, VLDL; D014280:Triglycerides; D002784:Cholesterol; D001629:Bezafibrate